In a recent study, precancerous pancreatic lesions and some pancreatic ductal adenocarcinoma (PDAC) tumors harboring KRAS ...
News-Medical.Net on MSN5h
FGFR2 identified as key driver in KRAS-mutated pancreatic cancer progressionPrecancerous pancreatic lesions and some pancreatic ductal adenocarcinoma (PDAC) tumors harboring KRAS mutations had ...
Precancerous pancreatic lesions and some pancreatic ductal adenocarcinoma (PDAC) tumors harboring KRAS mutations had ...
World Outcomes Of Non-Small Cell Lung Cancer Patients Harbouring Kras G12c And Kras G12d Mutations," published in the March ...
The decision to expand the development plan follows recently reported promising preclinical findings demonstrating that ...
2don MSN
Discover key insights from Edible Garden's Q4 2024 earnings call, highlighting 181.3% profit growth, strategic shifts, and plans for global expansion in 2025.
TheRas, Inc. d/b/a BridgeBio Oncology Therapeutics ("BBOT" or the "Company"), a clinical-stage biopharmaceutical company ...
Completed enrollment of Phase 2 AMPLIFY-7P randomized study; disease-free survival (“DFS”) event-driven interim analysis expected in Q3 ...
Mutant KRAS in ctDNA in patients with localized pancreatic cancer was shown to be a biomarker for metastatic progression and ...
RAS is the most frequently mutated oncogene in cancer, with KRAS mutations occurring in nearly one-quarter of all human cancers. RAS mutations impair the ability of RAS to convert from its active ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback